Advertisement

Pharmacological Approaches to Improve Surgical Outcomes After Retinal Reattachment Surgery

  • Mark S. Blumenkranz

Keywords

Retinal Detachment Retinal Pigment Epithelial Cell Diabetic Macular Edema Retinal Vein Occlusion Triamcinolone Acetonide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lincoff H, Kreissig I (1972) The treatment of retinal detachment without drainage of subretinal fluid. Trans Am Acad of Ophthalmol Otolaryngol 76:1221–1232Google Scholar
  2. 2.
    Han DP, Mohsin NC, Guse CE, Harz A, Tarkanian CN (1999) Comparison of pneumatic retinopexy and scleral buckling in the management of primary rhegmatogenous retinal detachment. Southern Wisconsin Pneumatic Retinopexy Study Group. Am J Ophthalmol 127:741–743Google Scholar
  3. 3.
    Campo RV, Sipperley JO, Sneed SR, Park DW et al (1999) Pars plana vitrectomy without scleral buckle for pseudophakic retinal detachments. Ophthalmology 106:1811–1815CrossRefPubMedGoogle Scholar
  4. 4.
    Brazitikos PD, Androudi S, D’Amico DJ, Papadopoulis N et al (2003) Perfluorocarbon liquid utilization in primary vitrectomy repair of retinal detachment with multiple breaks. Retina 23:615–621PubMedGoogle Scholar
  5. 5.
    Cowley M, Conway B, Campochiaro P, Kaiser D, Gaskin H (1989) Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol 107:1147–1151PubMedGoogle Scholar
  6. 6.
    Grizzard WS, Hilton GF (1982) Scleral buckling for retinal detachments complicated by periretinal proliferation. Arch Ophthalmol 100:419–422PubMedGoogle Scholar
  7. 7.
    Sternberg P Jr, Machemer R (1985) Results of conventional vitreous surgery for proliferative vitreoretinopathy. Am J Ophthalmol 100:141–146PubMedGoogle Scholar
  8. 8.
    Blumenkranz M, Hernandez E, Ophir A, Norton EWD (1984) 5-Fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 91:122–130PubMedGoogle Scholar
  9. 9.
    Blumenkranz MS (1988) Management of complicated retinal detachment. In: Tso MOM (ed) Retinal diseases: biomedical foundations and clinical management. JB Lippincott, PhiladelphiaGoogle Scholar
  10. 10.
    Asaria RH, Kon CH, Bunce C, Charteris DC et al (2001) How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology 108:1184–1186PubMedGoogle Scholar
  11. 11.
    Martidis A, Duker JS, Greenberg PB, Rogers AH et al (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927CrossRefPubMedGoogle Scholar
  12. 12.
    Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E (2002) Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 86:247–248CrossRefPubMedGoogle Scholar
  13. 13.
    Koerner F, Merz A, Gloor B, Wagner E (1982) Postoperative retinal fibrosis — a controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol 219:268–271CrossRefPubMedGoogle Scholar
  14. 14.
    Machemer R (1977) Massive periretinal proliferation: a logical approach to therapy. Trans Am Ophthalmol Soc 75:556–586PubMedGoogle Scholar
  15. 15.
    Blumenkranz MS, Hartzer MK (2000) The mechanism of action of drugs for the treatment of vitreoretinal scarring. In: Retina, vol. 3. Ryan S, Glaser B (eds) CV Mosby, St. Louis, pp 2281–2293Google Scholar
  16. 16.
    Campochiaro PA, Bryan JA III, Conway BP, Jaccoma EH (1986) Intravitreal chemotactic and mitogenic activity implications of blood-retinal barrier breakdown. Arch Ophthalmol 104:1685–1687PubMedGoogle Scholar
  17. 17.
    Campochiaro PA, Glaser BM (1986) Mechanisms involved in retinal pigment epithelial cell chemotaxis. Arch Ophthalmol 104:277–280PubMedGoogle Scholar
  18. 18.
    Yeo JH, Sadeghi J, Campochiaro PA, Green WR, Glaser BM (1986) Intravitreous fibronectin and platelet-derived growth factor: new model for tractional retinal detachment. Arch Ophthalmol 104:417–421PubMedGoogle Scholar
  19. 19.
    Verdoorn C, Renardel de Lavalette VW, Dalma-Weizhaus J, Orr GM, Sorgente N, Ryan SJ (1986) Cellular migration, proliferation and contraction: an in vitro approach to a clinical problem — proliferative vitreoretinopathy. Arch Ophthalmol 104:1216–1219PubMedGoogle Scholar
  20. 20.
    Vidaurri-Leal J, Glaser B (1984) Effect of fibrin on morphologic characteristics of retinal pigment epithelial cells. Arch Ophthalmol 102:1376–1379PubMedGoogle Scholar
  21. 21.
    Vidaurri-Leal J, Hohman R, and Glaser BM (1984) Effect of vitreous on morphologic characteristics of retinal pigment epithelial cells: a new approach to the study of proliferative vitreoretinopathy. Arch Ophthalmol 102:1220–1223PubMedGoogle Scholar
  22. 22.
    Blumenkranz MS, Ophir A, Claflin A, Hajek AS (1982) Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol 94:458–467PubMedGoogle Scholar
  23. 23.
    Stern WH, Lewis GP, Erickson PA, Guerin CJ, Anderson DH, Fisher SK, O’Donnell JJ (1983) Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol 96:33–42PubMedGoogle Scholar
  24. 24.
    Tano Y, Sugita G, Abrams G, Machemer R (1980) Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 89:131–136PubMedGoogle Scholar
  25. 25.
    Van Bockxmeer FM, Martin CE, Constable J (1985) Models for assessing scar tissue inhibitors. Retina 5:47–60PubMedGoogle Scholar
  26. 26.
    Wiedemann P, Lemmen K, Schmiedl R, Heimann K (1987) Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am J Ophthalmol 104:10–14PubMedGoogle Scholar
  27. 27.
    Anonymous (1992) Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1. Arch Ophthalmol 110:770–779Google Scholar
  28. 28.
    Anonymous (1992) Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 2. Arch Ophthalmol 110:780–792Google Scholar
  29. 29.
    Jolimaitre P, Malet-Martino M, Martino R (2003) Fluorouracil prodrugs for the treatment of proliferative vitreoretinopathy: formulation in silicone oil and in vitro release fluorouracil. Int J Pharm 259:181–192PubMedGoogle Scholar
  30. 30.
    Scott IU, Flynn HW Jr, Murray TG, Feuer WJ (2003) Perfluoron study group. Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study. Am J Ophthalmol 136:454–463PubMedGoogle Scholar
  31. 31.
    Blumenkranz MS, Claflin A, Hajek AS (1984) Selection of therapeutic agents for intraocular proliferative disease: cell culture evaluation. Arch Ophthalmol 102:598–604PubMedGoogle Scholar
  32. 32.
    Blumenkranz MS, Hartzer MK, Hajek AS (1987) Selection of therapeutic agents for intraocular proliferative disease. II. Differing anti-proliferative activity of the fluoropyrimidines. Arch Ophthalmol 105:396–399PubMedGoogle Scholar
  33. 33.
    Williams RG, Chang S, Comaratta M, Simoni G (1996) Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol 234: 496–503CrossRefPubMedGoogle Scholar
  34. 34.
    Peyman GA, Cheema R, Conway MD, Fang T (2000) Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 20:554–555PubMedGoogle Scholar
  35. 35.
    Barrada A, Peyman GA, Case J, Fishman G, Thomas A, Fiscella R (1984) Evaluation of intravitreal 5-fluorouracil, vincristine, VP16, doxorubicin, and thiotepa in primate eyes. Ophthalmic Surg 15:767–769PubMedGoogle Scholar
  36. 36.
    Berger AS, Cheng CK, Pearson A, Ashton P, Crooks P, Cynkowski T, Cynkowska G, Jaffe GJ (1996) Intravitreal sustained release corticosteroid-5-fluorouracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 37:2318–2325PubMedGoogle Scholar
  37. 37.
    Rubsamen PE, Davis P, Hernandez E, O’Grady G, Cousins SW (1994) Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch Ophthalmol 112: 407–413PubMedGoogle Scholar
  38. 38.
    Stern WH, Guerin CJ, Erickson PA, Lewis GP, Anderson DH, and Fisher SK (1983) Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol 96: 43–51PubMedGoogle Scholar
  39. 39.
    Hartzer MK, Blumenkranz MS, Hajek AS, Dailey WD, Cheng M, Margherio AS (1989) Selection of therapeutic agents for the treatment of intraocular proliferative disease. Part 3. Effects of fluoropyrimidines on cell-mediated contraction. Exp Eye Res 48:321–328PubMedGoogle Scholar
  40. 40.
    Berger AS, Cheng CK, Pearson A, Ashton P, Crooks P, Cynkowski T, Cynkowska G, Jaffe GJ (1996) Intravitreal sustained release corticosteroid-5-fluorouracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 37:2318–2325PubMedGoogle Scholar
  41. 41.
    Perkins SL, Galemore R, Yang CH, Guo H, Ashton P, Jaffe GJ (2000) Pharmacokinetics of the flucinolone/5-fluorouracil codrug in the gasfilled eye. Retina 20:514–519PubMedGoogle Scholar
  42. 42.
    Asaria RH, Kon CH, Bunce C, Charteris D, Wong D, Khaw P, Aylward G (2001) Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 108:1179–1183PubMedGoogle Scholar
  43. 43.
    Wiedemann P, Leinung C, Hilgers RD, Heimann K (1991) Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 229:150–152CrossRefPubMedGoogle Scholar
  44. 44.
    Campochiaro PA, Hackett SF, Conway BP (1991) Retinoic acid promotes density-dependent growth arrest in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 32:65–72PubMedGoogle Scholar
  45. 45.
    Mandava N, Blackburn P, Paul D, Wilson M, Read S, Alspaugh E, Tritz R, Barber J, Robbins J, Kruse C (2002) Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 43:3338–3348PubMedGoogle Scholar
  46. 46.
    Van Bockxmeer FM, Martin CE, Thompson DE, Constable J (1985) Taxol for the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 26: 1140–1147PubMedGoogle Scholar
  47. 47.
    Lemor M, Yeo JH, Slater B (1986) Oral colchicine for the treatment of experimental retinal detachment. Arch Ophthalmol 104:1226–1229PubMedGoogle Scholar
  48. 48.
    Blumenkranz M, Hartzer M, Iverson D (1992) An overview of potential applications of heparin in vitreoretinal surgery. Retina 12[Suppl]:S71–S74PubMedGoogle Scholar
  49. 49.
    Bratt G, Tornebohm E, Lockner D, Bergstrom K (1985) A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemost 53:208–211PubMedGoogle Scholar
  50. 50.
    Iverson DA, Katsura H, Hartzer MK, Blumenkranz MS (1991) Inhibition of intraocular fibrin formation following infusion of low-molecular weight heparin during vitrectomy. Arch Ophthalmol Vis Sci 109:405–409Google Scholar
  51. 51.
    Chapman C, Iverson D, Hartzer M, Minelli E, and Blumenkranz M (1992) The effect of low molecular weight heparin on proliferative vitreoretinopathy induced in the rabbit eye. Invest Ophthalmol Vis Sci 33[Suppl]:818Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Mark S. Blumenkranz

There are no affiliations available

Personalised recommendations